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Recent studies show a key role of brain inflammation in epilepsy. However, the
mechanisms controlling brain immune response are only partly understood. In the
periphery, acetylcholine (ACh) release by the vagus nerve restrains inflammation
by inhibiting the activation of leukocytes. Recent reports suggested a similar
anti-inflammatory effect for ACh in the brain. Since brain cholinergic dysfunctions
are documented in epileptic animals, we explored changes in brain cholinergic gene
expression and associated immune response during pilocarpine-induced epileptogenesis.
Levels of acetylcholinesterase (AChE) and inflammatory markers were measured using
real-time RT-PCR, in-situ hybridization and immunostaining in wild type (WT) and
transgenic mice over-expressing the “synaptic” splice variant AChE-S (TgS). One month
following pilocarpine, mice were video-monitored for spontaneous seizures. To test
directly the effect of ACh on the brain’s innate immune response, cytokines expression
levels were measured in acute brain slices treated with cholinergic agents. We report
a robust up-regulation of AChE as early as 48h following pilocarpine-induced status
epilepticus (SE). AChE was expressed in hippocampal neurons, microglia, and endothelial
cells but rarely in astrocytes. TgS mice overexpressing AChE showed constitutive
increased microglial activation, elevated levels of pro-inflammatory cytokines 48h after
SE and accelerated epileptogenesis compared to their WT counterparts. Finally we show
a direct, muscarine-receptor dependant, nicotine-receptor independent anti-inflammatory
effect of ACh in brain slices maintained ex vivo. Our work demonstrates for the first time,
that ACh directly suppresses brain innate immune response and that AChE up-regulation
after SE is associated with enhanced immune response, facilitating the epileptogenic
process. Our results highlight the cholinergic system as a potential new target for the
prevention of seizures and epilepsy.
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INTRODUCTION
Accumulating experimental evidence indicates that brain
immune response and inflammatory mediators decrease the
threshold for individual seizures and contributes to the process
of epileptogenesis (for review see: Vezzani and Granata, 2005;
Rijkers et al., 2009; Vezzani et al., 2011). Therefore, understanding
the mechanisms controlling the extent and duration of the brain’s
inflammatory response to status epilepticus (SE) and injury may
promote the understanding of epileptogenesis and highlight new
therapeutic targets for the prevention and treatment of epilepsy.
Peripheral inflammation is controlled, amongst others, by the
cholinergic anti-inflammatory pathway which involves inhibition
of innate immune responses by ACh released from the vagus
nerve. This mechanism is dependent on the alpha7 subunit of
the nicotinic acetylcholine receptor (α7nAChR), which inhibits
NF-kappaB nuclear translocation and suppresses cytokine release
by monocytes and macrophages (Tracey, 2002, 2009). Centrally
acting inhibitors of the ACh hydrolyzing enzyme, acetyl-
cholinesterase (AChE), were shown to enhance the peripheral
cholinergic anti-inflammatory pathway via central muscarinic
receptors (Pavlov et al., 2006, 2009). Recent reports point toward
a cholinergic anti-inflammatory mechanism also in the cen-
tral nervous system (CNS). In cultured microglia, ACh pre-
treatment inhibited lipopolysaccharide (LPS)-induced tumor
necrosis factor alpha (TNFα) release via α7nAChR (Shytle et al.,
2004). Accordingly, AChE inhibition reduced microglial produc-
tion of TNFα in a hypoxia model (Wang et al., 2010). AChE
inhibitors have also been shown to reduce glial activation and
inflammatory cytokine production in experimental autoimmune
encephalomyelitis (Nizri et al., 2008) and in a cerebral hypoper-
fusion model in the rat (Wang et al., 2010).
We recently reported cholinergic dysfunction and up-
regulation of AChE in temporal lobe structures of SE-experienced
epileptic rats (Zimmerman et al., 2008). These results raised the
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hypothesis that transcriptionally controlled cholinergic imbal-
ance may have a role in brain immune response during epilep-
togenesis. We thus used the pilocarpine model of epilepsy to
study AChE expression and the role of consequent cholinergic
imbalance on brain immune response and epileptogenesis.
MATERIALS AND METHODS
All animal experiments were approved by the Committee for
Ethics in Animal experimentation of the Faculty of Health
Sciences, Ben-Gurion University of the Negev. Wild type (WT)
FVB/N (Harlan Laboratories, Jerusalem), and transgenic mice
over-expressing human AChE-S (TgS) (Beeri et al., 1995) were
maintained on a 12 h light/dark cycle and had access to food and
water ad libitum. All chemicals were purchased from Sigma unless
otherwise mentioned.
PILOCARPINE TREATMENT
The well-established pilocapine model for temporal lobe epilepsy
was induced (Cavalheiro et al., 1996; Shibley and Smith, 2002;
Chen et al., 2005). Pilocarpine (290–340mg/kg i.p.) was injected
to adult (8–16 weeks old, 26–34 g BW) male mice 15min after
pre-treatment withmethyl-scopolamine (1.5mg/kg i.p.). Animals
were observed for 2 h after pilocarpine injection, and seizures
were evaluated according to a modified version of the Racine scale
(Racine, 1972; Borges et al., 2003). SE was defined by continu-
ous seizure activity consisting of stages 3.5–5 seizures, five taken
as the onset. Forty minutes from onset, SE was interrupted by
injection of diazepam (4mg/kg i.p.). Control mice were treated
with the same protocol, except that saline was injected instead of
pilocarpine, followed, 1 h later, by diazepam.
Epilepsy was diagnosed in the presence of at least one spon-
taneous stage five seizure observed during a 48 h period of
video-monitoring, 1–3 months after SE (in 11WT mice). For the
comparison of spontaneous seizures frequency between strains,
WT (eight mice) and TgS (12 mice) were simultaneously video-
monitored 1 month following SE.
PROCESSING OF TISSUE SAMPLES
Forty-eight hours after SE, animals were deeply anesthetized
with isofluorane and decapitated. For enzymatic activity and
RT-PCR, brains were quickly removed and the hippocampus
was dissected and frozen in liquid nitrogen. All tissues were
stored fresh at −80◦C. For native protein extraction, frozen
tissue was thawed and homogenized on ice with 200μl homog-
enization buffer (0.01M sodium phosphate pH 7.4, 1% triton,
4◦C). Lysates were pre-cleared by centrifugation at 17,000 rpm
at 4◦C for 30min, and the total protein concentration of
the supernatant was determined using Bradford solution (Bio-
Rad, Israel) (Bradford, 1976). Bovine serum albumin (BSA)
was used as a standard. The supernatants were kept on ice
until the cholinesterase assay was performed within 2 h after
homogenization. For histological staining, hemispheres were
either fixed in 4% paraformaldehyde (PFA) in phosphate buffer
saline (PBS) for 48 h and paraffin-embedded, or horizon-
tally sliced to 400μm sections, fixed in 4% PFA in phos-
phate buffer (PB) (0.1M Na2HPO4, 0.02M NaH2PO4, pH
7.4) and kept in 4◦C until re-slicing. Slices were immersed
in 30% sucrose overnight and then re-sliced to 30μm sec-
tions in a freezing microtome (Leica Microsystems, Wetzlar,
Germany).
KARNOVSKY-ROOT STAINING IN NON-DENATURING
ELECTROPHORESIS GEL AND BRAIN SECTIONS
Electrophoresis of active AChE was performed in non-denaturing
conditions. Fifty milligrams protein from each supernatant was
loaded on 7.5% vertical polyacrylamide gel at 4◦C for 1 h
(Bon et al., 1988). Migration was performed in the presence of
0.25% Triton X-100; AChE activity was revealed as reported by
Karnovsky and Roots (Karnovsky and Roots, 1964; Kaufer et al.,
1998). Bands intensity was quantified using a homemade MatLab
script. AChE activity staining was performed in 200μm fresh hor-
izontal sections using the same staining solution (Zimmerman
et al., 2008). Images were taken with a stereomicroscope (Zeiss,
Lumar.V12 and an AxiCamMRc5).
REAL-TIME RT-PCR, In-situ HYBRIDIZATION AND IMMUNOSTAINING
Real-time RT-PCR was performed using a standard protocol as
previously described (Zimmerman et al., 2008). Total RNA was
extracted using Absolutely RNA Miniprep Kit (Stratagene, CA,
USA), and reverse transcribed (300 ng) using Verso™ cDNA Kit
(Thermo, MA, USA). RT-PCR was performed using ABsolute™
QPCR SYBR® Green ROX (ABgene, UK) in a 7900HT Sequence
Detection System (Applied Biosystems, CA, USA). Quantification
was assessed at the logarithmic phase of the PCR reaction.
The PCR annealing temperature was 60◦C for all primer pairs
(Table 1). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as a house-keeping gene.
For double labeling histological experiments we combined
in-situ hybridization (FISH) with immunofluorescence (IF).
Stainings were done on seven μm-thick paraffin-embedded
sagittal sections or 30μm-thick freezing microtome horizon-
tal sections. Prior to staining, 30μm sections were washed
three times in PB and mounted on SuperFrost slides (Thermo,
MA, USA). FISH was performed as previously described
(Berson et al., 2008) with slight modifications: for antigen
retrieval, slides were soaked in 0.01M citrate buffer pH six,
heated in the micro-wave for 15min, washed in double-
distilled water and with PBT. Hybridization mix [including
50-mer 5′-biotinylated, 2-O-methylprotected complementary
RNA probes (Table 2) 10μg/ml] was applied for 10min in
60◦C and then for 90min in 52◦C (90min and overnight
respectively for 30μm sections). After washing with TBST
buffer (25mM Tris–HCl pH 7.5, 136mM NaCl, 2.7mM KCl,
0.05% Tween-20), slides were incubated in blocking solu-
tion for 30min. Primary antibodies (Table 3) diluted in the
blocking solution were incubated (90min) at room temper-
ature (30μm sections—overnight in 4◦C). After three rinses
in TBST, sections were incubated in a mix of streptavidin-
conjugated Cy2 and Cy3 or Cy5 conjugated goat IgG (Jackson
Immunoresearch, 1:100 dilution) in TBST for 1 h at room tem-
perature. Slides were then washed with TBST, and mounted with
ImmunoMount (Thermo, MA, USA). Slides stained for Iba1
were incubated in PBS with 0.5% Triton X-100 for 1 h, before
blocking.
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Table 1 | Primer pairs.
Gene Accession # Primers
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) NM017008 F(1242): GGGTGTGAACCACGAG
R(1417): AGGGGCCATCCACAGTCT
Acetylcholinesterase (AChE)S-variant AF002993 F(7855): CTTCTGGAACCGCTTCCTCCCCAAATT
R(6916): GTAGTGGTCGAACTGGTTCTTCCAGTGCAC
Acetylcholinesterase (AChE)R-variant AF002993 F(7855): CTTCTGGAACCGCTTCCTCCCCAAATT
R(7779): GGTTACACCTGGCGGGCTCC
Acetylcholinesterase (AChE)N-variant AY389979 F(188): AATGCTAGGCCTGGTGATGT
R(285): GGCAGTGGAAACTTCTGGA
Interleukin 1 beta (IL-1β) NM008361.3 F(368): GCCCATCCTCTGTGACTCAT
R(597): AGGCCACAGGTATTTTGTCG
Interleukin 12 (IL-12) M86672.1 F(600): CATCGATGAGCTGATGCAGT
R(762): CAGATAGCCCATCACCCTGT
Tumor necrosis factor alpha(TNF-α) NM013693 F(946): AGCCCCCAGTCTGTATCCTT
R(1157): CTCCCTTTGCAGAACTCAGG
High-mobility group box 1 (HMGB1) NM010439.3 F(4): ACAGAGCGGAGAGAGTGAGG
R(247): GGGTGCTTCTTCTTGTGCTC
Table 2 | Complementary RNA probes.
Probe Beginning point in the mouse AChE gene Sequence
mAChE-S Exon E6 position 1,392 5′-CCCCUAGUGGGAGGAAGUCGGGGAGGAGUGGACAGGGCCUGGGGGCUCGG-3′
mAChE-R Intron I4 position 74 5′-AACCCUUGCCGCCUUGUGCAUUCCCUGCUCCCCCCACUCCAUGCGCCUAC-3′
Table 3 | Dilution, blocking, and designated sections for all primary antibodies.
Primary antibody Source Dilution Blocking Designated sections
Mouse anti-GFAP Sigma 1:400 4% goat serum (Sigma) + 7μm-thick paraffin-
Rabbit anti-GAD65/67 Sigma 1:400 2% BSA (Sigma) embedded sections
Mouse anti-NeuN Chemicon 1:100 30μm-thick freezing
Rabbit anti-Iba1 Wako 1:1000 (+0.3% Dyna Antibody Diluant microtome sections
Triton X-100) (Dyna Scientific)
(+0.5% Triton X-100)
Abbreviations: GFAP, glial fibrillary acidic protein; GAD, glutamic acid decarboxylase; NeuN, neuronal nuclei; Iba1, ionized calcium binding adaptor molecule 1.
ACUTE SLICES PREPARATION AND DRUG APPLICATION
Preparation and maintenance of brain slices ex-vivo was per-
formed using standard procedures as previously reported
(Zimmerman et al., 2008). In short, mice (2–4 month old)
were deeply anesthetized; brains quickly removed and 400μm
horizontal slices were obtained (NVSLM1—motorized advance
vibroslice, WPI, USA). Slices were maintained in a standard
interface chamber at 36 ± 1◦C and were superfused with artifi-
cial cerebrospinal fluid (ACSF) contained (in mM): NaCl, 129;
NaHCO3, 21; NaH2PO4, 1.25; MgSO4, 1.8; CaCl2, 1.6; KCl, 3;
glucose, 10; pH 7.4. Treated slices were incubated simultaneously
with matched controls (in separate chambers). Drugs were added
to the bathing solution after 30min incubation with ACSF for
4 h. Slices were then transferred to liquid nitrogen for RT-PCR.
Drugs included carbamylcholine chloride (CCh, 50μM), acetyl-
choline (ACh 10 or 50μM), physostigmine (1μM), Atropine
(1μM), Mecamylamine (50μM), α-bungarotoxin (100μM) and
tetrodotoxine (TTX, 1μM).
MICROSCOPY AND IMAGE ACQUISITION
All fluorescent images were obtained using XYZ scanning with
an Olympus FluoView FV1000 confocal microscope (Olympus,
Hamburg, Germany) or with a Nikon inverted TI microscope
(Nikon, Japan) and a cooled 14 bit CCD camera (Coolsnap HQ2,
Photometrics, Tucson AZ). For quantification, Six to eight images
(×20) from non-overlapping hippocampal fields were taken from
each slice (three slices per animal, two to three animals per group)
using the same acquisition parameters. Analysis was done using a
homemade MatLab script: intensity values for each image were
normalized to the mean. A constant cut-off value was set to
establish a threshold defining background (“black”) and signal
(“white”) pixels. The total number of white pixels (stained area)
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for each binary image was summed and that value was later used
for statistical analysis.
STATISTICAL ANALYSIS
The non-parametric Mann–Whitney test, One-Way ANOVA,
Chi-square (χ2), and two-tailed independent student t-test were
applied (SPSS; SPSS Inc., Chicago, USA) as mentioned in the
text. P < 0.05 was considered significant. Data is expressed as the
mean ± SEM.
RESULTS
SE was achieved in 75.7% of mice injected with pilocarpine (n =
53 out of 70) with a mortality rate of 22.6%. In WT mice, 48 h
video-monitoring at 3 months after SE revealed a high percent-
age (n = 9 out of 11, 82%) of epileptic mice (≥1 spontaneous
unprovoked stage 5 seizure).
AChE IS UP-REGULATED DURING EPILEPTOGENESIS
As previous studies showed AChE upregulation in chronic epilep-
tic animals, we studied AChE expression 48 h after SE to challenge
the hypothesis that cholinergic imbalance occurs early during
the epileptogenesis process. All known alternatively spliced AChE
mRNA transcripts, including AChE-S, AChE-R, and N-AChE
were found to be significantly up-regulated in the hippocampus
of treated mice compared to saline-injected controls (Figure 1A).
Karnovsky–Root staining confirmed increased AChE activity in
hippocampal homogenates (Figure 1B) as well as in sections
obtained from SE-experienced mice (Figure 1C). Within the
hippocampus, AChE activity was most prominent in the stra-
tum molecular of the dentate gyrus, the stratum oriens of the
CA1 and CA3 regions, the subiculum and the entorhinal cortex
(Figure 1C).
To identify specific cell populations expressing AChE mRNA
following SE, we combined AChE FISH with immunostain-
ing against specific cell-type markers. FISH showed intensified
AChE expression in neurons within all regions of the hip-
pocampus, which was most prominent in the pyramidal cell
layer of all CA sub-regions (Figures 2A,B,G). In addition,
ACHE mRNA was co-localized with GAD positive inhibitory
interneurons in all hippocampal sub-regions (Figure 2H). We
further searched for AChE expression in glia cells, known
to be activated early following SE and suggested to play
a role in epileptogenesis (Borges et al., 2003; Turrin and
Rivest, 2004; Ivens et al., 2007; Pitkanen et al., 2007; David
et al., 2009). GFAP immunostaning indeed indicated a strong
astroglial activation after SE (Figures 2C,D); However, while
AChE mRNA was observed along blood vessels, probably in
endothelial cells, co-labeling experiments failed to reveal sig-
nificant ACHE mRNA expression within GFAP-positive astro-
cytes (Figures 2I,J). Conversely, in SE-exposed mice we found
a robust increase in immunolabeling for the microglia marker,
Iba1 (Figures 2E,F; p < 0.001; control: n = 47, treated: n = 70
fields from three sections per animal, 2/3 animals per group; inde-
pendent t-test), co-labeled with a strong FISH signal for AChE
mRNA (Figures 2K,L). In addition, Iba1 positive cells follow-
ing SE presented perikaryal hypertrophy and processes retraction
(Figure 2L), a clear morphological pattern for their activation
(Rappold et al., 2006).
BRAIN AChE LEVELS AND LOCAL IMMUNE RESPONSE
The rapid up-regulation and expression pattern of AChE after SE
together with the known cholinergic control of immune response
in the periphery led us to challenge the hypothesis that the
observed cholinergic imbalance is sufficient to induce a local
innate immune response within the brain. We thus tested the
immune response in transgenic mice with a constitutive over-
expression of the human synaptic variant of acetylcholinesterase
(AChE-S) (TgS) before and 48 h following SE. In TgS mice, show-
ing 50% more AChE activity than WT animals (Beeri et al., 1995;
and Figure 3A), immunolabeling against Iba1 was significantly
FIGURE 1 | AChE up-regulation 48 h post SE. (A) expression levels of
AChE-S, AChE-R, and N-AChE 48 h after SE, as revealed by real-time RT-PCR
(p = 0.05, 0.053, and 0.025 respectively; n = 5 controls, n = 3 or 4 treated;
mean ± SEM; Mann–Whitney test). (B) Top: Karnovsky–Roots staining on
non-denatured activity gel of control and 48h after SE samples. Bottom: gel
quantification (p = 0.05; n = 3; mean ± SEM; Mann–Whitney test).
(C) Karnovsky–Roots staining of 200μm horizontal brain sections from
control and 48 h post SE mice. C, control; T, treated.
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FIGURE 2 | AChE expression in the hippocampus. (A,B) FISH for AChE-R
in the hippocampus of control (A) and 48h after SE (B) mice. (C,D) GFAP
staining in the hippocampus of control (C) and 48h post SE (D) mice.
(E,F) Iba1 staining in the hippocampus of control (E) and 48 h post SE (F)
mice. (G) Double labeling of AChE (green) and NeuN (red) in CA1 area of a
treated animal. (H) Double labeling of AChE (green) and GAD65/67 (red) in
the hilus of a treated animal. (I,J) Double labeling of AChE (green) and GFAP
(red) in hippocampus of control (I) and treated (J) mice (scale 10μm). Note
the clear positive AChE staining in the blood vessel and the endothelial cells
but not in the end fit of GFAP-positive astrocytes surrounding it. (K,L) Double
labeling of AChE (green) and Iba1 (red) in hippocampus of control (K) and
treated (L) mice (scale 10μm).
increased compared to WT (p = 0.046; WT: n = 47, TgS: n = 70
fields from three sections per animal, 2/3 animals per group;
independent t-test). This increase was associated with upregu-
lation of mRNA for high mobility group box 1 (HMGB1)—a
pro-inflammatory cytokine-like mediator expressed in activated
microglia (Lotze and Tracey, 2005; Kim et al., 2006; Hayakawa
et al., 2008) (Figure 3F; p = 0.014). Forty-eight hours following
SE both WT and TgS mice showed higher labeling of Iba1 com-
pared to their matched controls (Figure 3B); However, treated
TgSmice showed significantly higher (30%) labeling compared to
that observed in treated WTs (17%) (p = 0.043; control: n = 47,
treated: n = 71 fields from three sections per animal, 2/3 ani-
mals per group; independent t-test). In addition, up-regulation
of IL-1β and IL-12 was significantly higher in TgS mice com-
pared to WT (Figures 3C,D). SE-induced up-regulation of TNFα
mRNA was similar in both WT and TgS mice (Figure 3E).
HMGB1 was also upregulated (p = 0.027) in WT exposed to
SE and matched the already high levels in non-treated TgS
(Figure 3F).
TgS MICE OVER-EXPRESSING AChE SHOW ACCELERATED
EPILEPTOGENESIS
To test whether the observed increase in immune response
in treated TgS mice is associated with altered epileptogenesis
(Vezzani et al., 2008), we video-monitored WT and TgS mice
for 48 h one month after SE. Importantly, no differences in the
acute response to pilocarpine (rate of SE, delay to SE, seizure
phenotypes, response to diazepam or survival) were observed
between WT and TgS mice (Figures 4A–C). In contrast, video-
monitoring at 1 month uncovered a significantly higher rate of
TgS mice presenting spontaneous seizures compared to WT mice
(Figure 4D). These results support the notion that AChE over-
expression is associated with enhanced immune response and
facilitated epileptogenesis.
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FIGURE 3 | Compared microglia status in WT and TgS mice.
(A) Karnovsky–Roots staining of 200μm horizontal brain sections from
naïve WT and TgS mice. (B) Iba1 staining in the hippocampus of
control WT (B1), control TgS (B2), treated WT (B3), and treated TgS (B4)
mice. (C–F) Real-time RT-PCR for key inflammatory cytokines. (C) IL-1β
mRNA relative levels (∗p = 0.014; ∗∗p = 0.004). (D) IL-12 mRNA
relative levels (∗p = 0.014; ∗∗p = 0.004). (E) TNFα mRNA relative levels.
WT: p = 0.027, TgS: p = 0.054. (F) HMGB1 mRNA relative levels.
p < 0.05 (see text). (WT: n = 5 controls, n = 4 treated, TgS: n = 6
controls/treated. In F; TgS control: n = 4; C, control; T, treated; Statistical
analysis was done using the non-parametric Mann–Whitney test, mean ±
SEM.)
CHOLINERGIC ACTIVATION IS ANTI-INFLAMMATORY IN
HIPPOCAMPAL SLICES
Our results suggested that the rapid up-regulation of AChE fol-
lowing SE is associated with enhanced local immune response.
To explore to what extent this effect is associated with reduced
cholinergic control over the brain innate immune response, we
studied the immune response in acute brain slices maintained ex-
vitro 4 h following the slicing procedure.We hypothesized that the
injury associated with the slicing procedure would activate a sig-
nificant inflammatory response (Lucas et al., 2006) which could
be suppressed by cholinergic stimuli. Indeed, cholinergic activa-
tion by 50μM CCh reduced mRNA levels of IL1β and TNFα
(Figure 5A). Similar results were found with low levels of the
physiological agonist, ACh (10μM), in the presence of the AChE
inhibitor physostigmine (1μM, Figure 5A). The addition of TTX
did not prevent CCh action on the immune response, suggesting
it is not dependent on neuronal firing (Figure 5B). Importantly,
while the non-specific muscarinic receptor antagonist atropine
blocked the cholinergic-suppression of inflammatory response,
the non-specific nicotinic receptor antagonist, mecamylamine
(50μM) or the α7 nicotinic receptor antagonist α-bungarotoxin
(100 nM) did not (Figure 5B and data not shown).
DISCUSSION
In this study we offer experimental evidence indicating that (1)
cholinergic imbalance due to upregulation of AChE within the
hippocampus is associated with a local immune response; (2)
such imbalance and the associated inflammation following SE is
associated with epileptogenesis; and (3) ACh acts directly as a
modulator of brain innate immune response and thereby affect
epileptogenesis.
AChE is the fastest enzyme in mammalian cells and as the
enzyme in charge of executing ACh breakdown it is a key compo-
nent of cholinergic signaling (Meshorer and Soreq, 2006). AChE
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FIGURE 4 | SE and spontaneous seizures in TgS and WT mice. (A) Time
(in min) was measured from pilocarpine injection to onset of SE.
(B) Percentage of mice achieving SE. (C) Percentage of mice surviving
40min of SE (total number of injected animals: WT: n = 33, TgS: n = 44).
(D) Percentage of mice presenting spontaneous seizures 1 month after SE
(∗p = 0.019, Chi-square test; number of monitored animals: WT: n = 8,
TgS: n = 12).
levels are controlled via transcriptional and post-transcriptional
mechanisms and are dramatically increased under toxicological,
physical and psychological stress (Kaufer et al., 1998; Shohami
et al., 2000; Meshorer et al., 2002). This fast and robust increase in
AChE levels in response to neuronal activation has been suggested
to act as an homeostatic control to reduce neuronal excitabil-
ity (Meshorer et al., 2005b) and on the long-run this response
was reported to be associated with enhanced network excitability
(Meshorer et al., 2002; Zimmerman et al., 2008). These previ-
ous findings raised the hypothesis that AChE will be similarly
up-regulated following SE in the pilocarpine model of epilepsy.
Indeed, 48 h following SE we recorded increased AChE mRNA
and protein levels in SE-experienced mice. Unlike milder and
more specific stress manipulations (e.g., psychological) where
upregulation was reported to include the readthrough alterna-
tively spliced AChE-R variant (Kaufer et al., 1998; Meshorer et al.,
2002), SE was associated with a significant increase in mRNA lev-
els of all three alternatively spliced transcripts (Figure 1). In this
study we used the muscarinic agonist, pilocarpine, to induce SE
and thus it is possible that AChE upregulation represents a specific
response to the activation of muscarinic receptors. While we can-
not entirely exclude this possibility, it seems unlikely in light of a
similar up-regulation observed in the brains from chronic epilep-
tic rats following kainic acid-induced SE (Zimmerman et al.,
2008). The presence of c-fos binding sites in the promoter of
the gene encoding AChE (Meshorer et al., 2004) further sug-
gest that its upregulation is part of the transcriptional response
to excess neuronal activation. AChE transcripts were found in
both principle and inhibitory interneurons, supporting its role
in controlling the hyperexcitable network. In addition, follow-
ing SE high expression levels of AChE mRNA were also found
in morphologically identified endothelial cells, suggesting it may
have a role in vascular changes observed following SE, specifically
the robust increase in blood-brain barrier (BBB) permeability
(van Vliet et al., 2007; Weissberg et al., 2011). This notion is
supported by reports on compromised BBB in transgenic mice
over-expressing AChE (Meshorer et al., 2005a). The activation
of the immune system, and specifically HMGB1 upregulation in
these transgenic animals (Figure 3) may also underlie BBB open-
ing (Zhang et al., 2011). AChE transcripts were not found in
GFAP positive astrocytes, despite their robust activation during
SE. These results are consistent with a previous report showing
AChE activity in different lines of neuronal and non-neuronal
cells except for astrocytes (Thullbery et al., 2005), althoughmixed
astroglia cells were reported to upregulate the readthrough ACHE
transcript following oxidative stress in culture (Bond et al., 2006).
High expression levels of ACHE transcripts were found in Iba1
positive microglia following SE and to much less extent in con-
trol animals. These results together with the well-described brain
immune activation following SE (review by Vezzani et al., 2011)
raised the hypothesis that AChE upregulation in microglia may
have a role in modulating the innate immune response. This
hypothesis is supported by previous studies showing that in
microglial cell cultures AChE induces changes in cell morphol-
ogy as well as iNOS upregulation (von Bernhardi et al., 2003).
That the AChE effect is likely to be associated with choliner-
gic signaling is suggested by the observation that ACh inhibits
LPS-induced TNFα release in microglia cultures, an effect atten-
uated by α-bungarotoxin (Shytle et al., 2004). To test directly the
role of AChE overexpression on microglia functions we studied
transgenic mice with CNS limited, constitutive up-regulation of
synaptic AChE-S (Sternfeld et al., 2000). Indeed, the increase in
AChE activity led to increased immunostaining of the microglial
marker Iba1 and significant upregulation of mRNA levels for
HMGB1 (Figure 3), a newly defined cytokine that can be passively
released from necrotic cells or actively released from immune
activated cells (Wang et al., 1999; Abraham et al., 2000). Our
finding showing that AChE over expression in transgenic ani-
mals facilitated epileptogenesis are consistent with recent reports
showing a proconvulsant effect of HMGB1 in kainic acid treated
mice (Maroso et al., 2010). It is worth noticing that TgS mice
showed a robust increase in IL-1β expression (18-fold higher
than WT mice) 48 h following SE, consistent with the well-
described epileptogenic effects of IL-1β (Vezzani et al., 1999;
Friedman and Dingledine, 2011). Facilitated epileptogenesis in
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FIGURE 5 | Real-time RT-PCR for IL-1β and TNF-α in acute slices.
(A) mRNA relative levels in slices treated with aCSF, 50μM CCh (∗p = 0.025;
n = 6) or 1μM physostigmine with 10μM ACh (∗∗p = 0.006; n = 5–6).
(B) mRNA relative levels in slices treated with 50μM CCh (n = 5) and 50μM
CCh with 1μM atropine (∗p = 0.028; n = 5), 100 nM BTX (n = 5) or 1μM TTX
(∗p = 0.027; n = 4). Statistical analysis was done using the non-parametric
Mann–Whitney test, mean ± SEM. Physo, physostigmine; BTX,
bungarotoxine.
TgS mice could not be solely attributed to enhanced seizure activ-
ity due to increased network sensitivity to ACh (Meshorer et al.,
2002) since the latency and duration of SE in response to pilo-
carpine were similar in WT mice. This strengthens the notion
that AChE upregulation following SE is a response to excess neu-
ronal activation rather than a direct effect of pilocarpine. We
cannot rule out at this stage the contribution of other epilep-
togenic mechanisms including vascular changes (i.e., enhanced
BBB permeability) (Marchi et al., 2007; Friedman et al., 2009)
or changes in peripheral immune response (Fabene et al., 2008;
Marchi et al., 2009). When monitoring WTs for 1–3 month, 82%
showed spontaneous seizures, while TgS were not monitored at
such a late time point. Therefore, it is feasible that the rate of
epileptogenesis and not the end result are different between the
strains.
The most direct evidence for cholinergic control over the
innate immune response is given in the acute slices experiments
demonstrating that adding ACh or CCh to the bathing solution
suppressed mRNA levels of IL-1β and TNF-α. In accordance with
these results, previous studies demonstrated anti-inflammatory
effect for ACh and AChE inhibitors in glial cultures (Shytle et al.,
2004; Wang et al., 2010) and for AChE inhibitors in animals
(Nizri et al., 2008; Wang et al., 2008, 2010). It is important to
note that exposure to centrally acting potent AChE inhibitors
induces SE and neuroinflammation that may promote epilep-
togenesis (Dhote et al., 2007, 2012; De Araujo Furtado et al.,
2010). Thus, it seems clear that AChE inhibition per se, per-
haps due to enhanced neuronal excitability is usually associated
with increased brain inflammation and the transient increase in
ACh levels are not sufficient to block completely the brain innate
immune processes associated with SE and chronic recurrent
seizures (Pernot et al., 2009). Unlike previous studies (mostly
in the peripheral nervous system) (Tracey, 2002, 2007; Shytle
et al., 2004; Wang et al., 2008), our findings point to muscarinic
dependant activation as the underlying pathway. Although mus-
carinic receptors in the CNS were shown to control the periph-
eral nicotinic pathway, hinting to complex interactions between
the involved pathways (Pavlov et al., 2006, 2009), these inter-
actions could not explain the observations in the ex-vivo slice
preparation. Since recent studies did show that cytokines act as
pro-convulsants (Vezzani et al., 2011), their upregulation may
also be attributed to a positive feedback enhancement mecha-
nism. However, it is noteworthy that the sodium channel blocker,
TTX had no effect on cholinergic-suppression of cytokine pro-
duction suggesting that this cholinergic effect is independent of
neuronal firing.
In summary, our study suggests for the first time, a role
for activity-dependant cholinergic imbalance in brain immune
response, epileptogenesis and seizures and may offer a new basis
for understanding the role of AChE-inhibitors in the treatment
of Alzheimer’s disease and similar neurodegenerative disorders.
Future studies are warranted to delineate the contribution of
cholinergic signaling to brain immune response in neurologi-
cal and neurodegenerative disorders where immune response has
been reported (Amor et al., 2010) as well as its potential as a novel
target in the treatment of uncontrolled brain immune response.
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